Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study
PUBT · 06/03 12:01
Share
Listen to the news
- Medicus submitted a Phase 2b registrational protocol for SkinJect in Gorlin syndrome under its existing FDA IND.
- Trial targets up to 50 patients; primary endpoint is complete visual clearance in at least 50% of selected lesions at Week 10.
- FDA orphan drug designation application filed in April; incentives could include waiver of NDA fees above USD 5 million, seven years of exclusivity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved